Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q3)Sep 30, 2025 | (Q2)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Oct 31, 2023 | (FY)Jul 31, 2023 | (Q4)Jul 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating revenue | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
| Cost of revenue | ||||||||||
| Gross profit | ||||||||||
| Operating expense | -62.43%204K | -10.80%314K | 353K | 20,237.60%2.24M | 8,851.99%785K | 72,300.00%543K | 46,833.33%352K | 2.22K | 11.02K | 8.77K |
| Selling and administrative expenses | -64.66%88K | -26.57%105K | --199K | 8,657.60%965K | 4,438.72%398K | 33,100.00%249K | 18,966.67%143K | --2.22K | --11.02K | --8.77K |
| -General and administrative expense | -64.66%88K | -26.57%105K | --199K | 8,657.60%965K | 4,438.72%398K | 33,100.00%249K | 18,966.67%143K | --2.22K | --11.02K | --8.77K |
| Research and development costs | -60.54%116K | 0.00%209K | --154K | --1.28M | --387K | --294K | --209K | ---- | ---- | ---- |
| Operating profit | 62.43%-204K | 10.80%-314K | -353K | -20,237.60%-2.24M | -8,851.99%-785K | -72,300.00%-543K | -46,833.33%-352K | -2.22K | -11.02K | -8.77K |
| Net non-operating interest income (expenses) | -73.61%19K | -74.66%37K | 43K | -42K | -113K | 72K | 146K | |||
| Non-operating interest income | -73.97%19K | -74.66%37K | --43K | --99K | --26K | --73K | --146K | ---- | ---- | ---- |
| Non-operating interest expense | --0 | --0 | --0 | --141K | --139K | --1K | --0 | ---- | ---- | ---- |
| Other net income (expenses) | -4M | |||||||||
| Special income (charges) | ---- | ---- | --0 | ---4M | ---- | ---- | ---- | ---- | ---- | ---- |
| -Less:Restructuring and mergern&acquisition | ---- | ---- | --0 | --4M | ---- | ---- | ---- | ---- | ---- | ---- |
| -Less:Other special charges | ---- | ---- | ---- | --4M | ---- | ---- | ---- | ---- | ---- | ---- |
| Income before tax | 60.72%-185K | -34.47%-277K | -310K | -56,919.69%-6.28M | -134,497.42%-4.9M | -62,700.00%-471K | -27,366.67%-206K | -2.22K | -11.02K | -3.64K |
| Income tax | ||||||||||
| Earnings from equity interest net of tax | ||||||||||
| Net income | 60.72%-185K | -34.47%-277K | -310K | -56,919.69%-6.28M | -134,497.42%-4.9M | -62,700.00%-471K | -27,366.67%-206K | -2.22K | -11.02K | -3.64K |
| Net income continuous operations | 60.72%-185K | -34.47%-277K | ---310K | -56,919.69%-6.28M | -134,497.42%-4.9M | -62,700.00%-471K | -27,366.67%-206K | ---2.22K | ---11.02K | ---3.64K |
| Noncontrolling interests | ||||||||||
| Net income attributable to the company | 60.72%-185K | -34.47%-277K | -310K | -56,919.69%-6.28M | -134,497.42%-4.9M | -62,700.00%-471K | -27,366.67%-206K | -2.22K | -11.02K | -3.64K |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | ||||||||||
| Net income attributable to common stockholders | 60.72%-185K | -34.47%-277K | -310K | -56,919.69%-6.28M | -134,497.42%-4.9M | -62,700.00%-471K | -27,366.67%-206K | -2.22K | -11.02K | -3.64K |
| Diluted earnings per share | 0 | 0 | 0 | 0 | -134,714.52%-0.2508 | -63,355.26%-0.0241 | -27,652.63%-0.0105 | -0.0001 | -0.0006 | -0.0002 |
| Basic earnings per share | 0 | 0 | 0 | 0 | -134,714.52%-0.2508 | -63,355.26%-0.0241 | -27,652.63%-0.0105 | -0.0001 | -0.0006 | -0.0002 |
| Dividend per share | ||||||||||
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.